Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers. We are also more broadly interested in the potential to target GPR65 for benefit in a range of other serious diseases.Pathios employs a cutting-edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios has identfied GPR65 as a key innate immune checkpoint on TAMs and now aims to rapidly deliver on the promise of novel therapeutic agents targeting this receptor. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.

Canaan Partners

Medical Research Commercialisation Fund (MRCF)

Pathios Therapeutics 

Pathios Therapeutics is a drug discovery and development company founded in 2017, based in Oxford, UK. The company focuses on leveraging a deep understanding of the biology of the acidic tumor microenvironment (TME) and the immune cell receptor GPR65 to develop drugs that block GPR65, aiming to unlock the power of the immune system in the fight against cancer.

COM:PATHIOSTHERAPEUTICS

Pathios Therapeutics

Filings Not Available